ArticleOncology letters2016

Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer.

Xuefei Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.